News
| 3 min read
Gene therapies dominated the news this week, with positive results for both a CRISPR and non-viral therapy, and a U-turn decision from the FDA.
| 3 min read
As a new wave of chronic cough therapeutics enters clinical development, researchers are questioning whether the tools used to measure treatment effects are up to the task.
| 3 min read
The novel platform, called single-cell spatial pharmacobiology, revealed new insights into drug delivery of an antibody in Phase 1 trials.
| 5 min read
The field's foundational biology is no longer the limiting factor. What comes next depends on whether the industry can build the manufacturing, commercial, and clinical infrastructure to match what the science already knows how to do.
| 4 min read
Two year trial results position Gazyva as a potential first approved therapy for an autoimmune kidney disease with longstanding unmet need.
| 4 min read
Two reports landed the same week: one documenting rising pandemic risk, the other showing how little of the antiviral pipeline is ready to meet it. Then Ebola was declared a public health emergency.
| 4 min read
A first-in-human trial shows how computationally designed antigens could help shift vaccines from reactive to future-proof.
| 3 min read
The MHRA-led sandbox will generate real-world evidence on AI tools that could improve medicines safety, reduce late-stage failures, and accelerate drug development.
| 4 min read
Microbubble-based genetic medicines, pharma deals, trial misses, and more led the news this week.
| 6 min read
Long framed as a gynecological condition, PMOS is now understood as a multisystem disorder with metabolic, psychological, and cardiovascular consequences.
| 5 min read
The FDA announced interest in advancing drug repurposing programs across a wide variety of conditions, though challenges remain.
| 4 min read
A rare immune cell subset with the capacity to self-renew, persist long-term, and drive potent antitumor responses
